Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke

The Big Heart Disease Lie

Cure Heart Disease Forever

Get Instant Access

The second attempt to extend the time window of rtPA administration was the Alteplase Throm-bolysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study (45 ). Like ECASS II, ATLANTIS was originally designed to show if the benefits of systemic thrombolysis could extend up to 6 hr. After the publication of the NINDS study in 1995, the time window for enrollment was changed to encompass 3 to 5 hr. The primary endpoint for the modified study was good outcome, defined as an NIHSS score of 0 or 1 at 90 days. After 761 patients had been enrolled in ATLANTIS, the trial was terminated prematurely because of projected lack of benefit with active treatment. Again, no difference in mortality was observed between the 2 treatment groups, suggesting that "delayed" administration of rtPA was safe. The ATLANTIS investigators followed the precedent observed in ECASS II by concluding that the use of rtPA for acute ischemic stroke should not be undertaken after 3 hr.

Was this article helpful?

0 0
Your Heart and Nutrition

Your Heart and Nutrition

Prevention is better than a cure. Learn how to cherish your heart by taking the necessary means to keep it pumping healthily and steadily through your life.

Get My Free Ebook

Post a comment